Tricyclic pyrazole sulphonamide compunds and methods of making and using same

Patent metadata

Field	Value
Publication number	US-9242997-B2
Application number	US-201214116029-A
Country	US
Kind code	B2
Filing date	May 7, 2012
Priority date	May 6, 2011
Publication date	Jan 26, 2016
Grant date	Jan 26, 2016

Abstract

The invention provides tricyclic sulfonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

First claim

What is claimed is:

1. A tricyclic compound represented by:

wherein:
D 1 and D 2 are each 6-7 membered heterocyclic or heteroaromatic rings in which one of the two atoms in common between rings B and D is nitrogen and the other is carbon;
X 1 is selected from the group consisting of: *—C(R D1 R D2 )—C(R D5 R D6 )— # , *—C(R C1 )═C(R C2 )— # , and *—C(R D1 R D2 )—C(R D3 R D4 )—C(R D5 R D6 )— # ; wherein the * and # denote the attachment points of X 1 in Formula I;
X 2 is selected from the group consisting of: *—W 1 —C(R D5 R D6 )— # , *—W 1 C(R D3 R D4 )—C(R D5 R D6 )— # , and *—C(R D1 R D2 )—W 2 —C(R D5 R D6 )— # ; wherein the * and # indicate the attachment points of X 2 in Formula II;
Y is N in formula I, and Y is selected from CH or N in formula II;
B 1 or B 2 rings are each optionally be substituted by one or more fluorine atoms on any of the available carbon atoms;
W 1 is O;
W 2 is O;
A is phenyl;
R A1 is selected, independently for each occurrence, from the group consisting of: hydrogen, hydroxyl, cyano, halogen, C 1-4 alkyl or C 1-3 alkoxy; wherein C 1-4 alkyl, or C 1-3 alkoxy may be optionally substituted by one or more fluorines;
n is 1 or 2;
R A2 is selected from the group consisting of: hydrogen, R i R j N—, heterocyclyl, heterocyclyloxy, heterocyclyl-(NR a )—; wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R g and wherein if said heterocyclyl contains a —NH moiety that nitrogen may optionally be substituted by one or more groups R h ; or
R A2 is selected from the group consisting of: C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 1-6 alkoxy, C 3-6 alkenyloxy, C 3-6 alkynyloxy, C 3-6 cycloalkoxy, C 1-6 alkyl S(O) w — (wherein w is 0, 1 or 2), C 1-6 alkyl-N(R a )—, C 1-6 alkyl-N(R a )-carbonyl-, C 1-6 alkylcarbonyl-N(R a )—, C 1-6 alkyl-N(R a )-carbonyl-N(R a )—, C 1-6 alkyl-N(R a )—SO 2 —, C 1-6 alkyl-SO 2 —N(R a )—, C 1-6 alkoxycarbonyl-N(R a )—, C 1-6 alkylcarbonyl-N(R a )—C 1-6 alkyl-, C 1-6 alkyl-N(R a )-carbonyl-C 1-6 alkyl-, C 1-6 alkoxyC 1-6 alkyl-; wherein C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 1-6 alkoxy, C 3-6 alkenyloxy, C 3-6 alkynyloxy, C 3-6 cycloalkoxy, C 1-6 alkyl-S(O) w — (wherein w is 0, 1 or 2), C 1-6 alkyl-N(R a )—, C 1-6 alkyl-N(R a )-carbonyl-, C 1-6 alkylcarbonyl-N(R a )—, C 1-6 alkyl-N(R a )-carbonyl-N(R a )—, C 1-6 alkyl-N(R a )—SO 2 —, C 1-6 alkyl-SO 2 —N(R a )—, C 1-6 alkoxycarbonyl-N(R a )—, C 1-6 alkylcarbonyl-N(R a )C 1-6 alkyl-, C 1-6 alkyl-N(R a )-carbonyl-C 1-6 alkyl-, C 1-6 alkoxy-C 1-6 alkyl may optionally be substituted by R P , phenyl, phenoxy, heteroaryl, heteroaryloxy, heteroaryl-(NR a )—, heterocyclyl, heterocyclyloxy or heterocyclyl-N(R a )—; wherein said heteroaryl or phenyl may optionally be substituted with one or more substituents selected from R f ; wherein said heterocyclyl may optionally be substituted by one or more substituents selected from R g ; and wherein if said heterocyclyl contains a —NH moiety that nitrogen may optionally be substituted by one or more groups R h ;
R D1 and R D2 are each independently selected from the group consisting of: hydrogen, fluorine, hydroxyl, C 1-2 alkyl or C 1-2 alkoxy; wherein the C 1-2 alkyl and C 1-2 alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano or hydroxyl;
R D3 and R D4 are each independently selected from the group consisting of: hydrogen, fluorine, hydroxyl, cyano, C 1-3 alkyl or C 1-3 alkoxy; wherein the C 1-3 alkyl and C 1-3 alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or N(R a R b );
R D5 and R D6 are each independently selected from the group consisting of: hydrogen, fluorine, hydroxyl, cyano, C 1-2 alkyl or C 1-2 alkoxy; wherein the C 1-2 alkyl and C 1-2 alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or N(R a R b ),
R C1 is selected from the group consisting of: hydrogen, halogen, C 1-2 alkyl or C 1-2 alkoxy; wherein the C 1-2 alkyl or C 1-2 alkoxy may optionally be substituted by one or more fluorine atoms;
R C2 is selected from the group consisting of: hydrogen, halogen, hydroxyl, cyano, C 1-2 alkyl or C 1-2 alkoxy; wherein the C 1-2 alkyl and C 1-2 alkoxy may optionally be substituted by one or more fluorine atoms or a group selected from cyano, hydroxyl or N(R a R b );
R a and R b are independently selected, for each occurrence, from the group consisting of: hydrogen and C 1-3 alkyl; wherein C 1-3 alkyl may optionally be substituted by one or more substituents selected from: fluorine, cyano, oxo and hydroxyl;
or R a and R b , together with the nitrogen to which they are attached, form a 4-6 membered heterocyclic ring which may have an additional heteroatom selected from O, S, or N; and wherein the 4-6 membered heterocyclic ring may optionally be substituted on carbon by one or more substituents selected from the group consisting of: fluorine, cyano, oxo or hydroxyl;
R f is independently selected, for each occurrence, from the group consisting of: R P , hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 1-6 alkoxy, C 1-6 alkyl-S(O) w — (wherein w is 0, 1 or 2), C 1-6 alkylcarbonyl-N(R a )—; C 1-6 alkoxycarbonyl-N(R a )—; and wherein C 1-6 alkyl, C 3-6 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 1-6 alkoxy, C 1-6 alkyl-S(O) w —, C 1-6 alkylcarbonyl-N(R a )—, C 1-6 alkoxycarbonyl-N(R a )— may be optionally substituted by one or more substituents selected from R P ;
R g is independently selected for each occurrence from the group consisting of: R P , hydrogen, oxo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 1-6 alkoxy, C 1-6 alkyl S(O) w — (wherein w is 0, 1 or 2), C 1-6 alkylcarbonyl-N(R a )—, C 1-6 alkoxycarbonyl-N(R a )—; wherein C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 1-6 alkoxy, C 1-6 alkyl-S(O) w —,C 1-6 alkylcarbonyl-N(R a )—, C 1-6 alkoxycarbonyl-N(R a )— may be optionally substituted by one or more substituents selected from R P ;
R h is independently selected for each occurrence from the group consisting of: hydrogen, C 1-6 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, C 3-6 cycloalkyl, C 1-6 alkyl-S(O) 2 —, C 1-6 alkoxycarbonyl-, R i R j N-carbonyl-, R i R j N—SO 2 —; wherein C 1-6 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, C 3-6 cycloalkyl, C 1-6 alkyl-S(O) 2 —, C 1-6 alkylcarbonyl- may optionally be substituted by one or more substituents selected from R P ;
R i and R j , are selected independently for each occurrence from the group consisting of: hydrogen, C 1-4 alkyl and C 3-6 cycloalkyl; wherein C 1-4 alkyl and C 3-6 cycloalkyl may be optionally substituted by one or more substituents selected from fluorine, hydroxyl, cyano, R a R b N—, R a R b N-carbonyl-, C 1-3 alkoxy;
or R i and R j taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which may have an additional heteroatom selected from O, S, or N, optionally substituted on carbon by one or more substituents selected from the group consisting of: fluorine, hydroxyl, oxo, cyano, C 1-6 alkyl, C 1-6 alkoxy, R a R b N—, R a R b N—SO 2 —, R a R b N-carbonyl-; and wherein said C 1-6 alkyl or C 1-6 alkoxy may optionally be substituted by fluorine, hydroxyl or cyano; and optionally substituted on nitrogen by one or more substituents selected from the group consisting of: C 1-6 alkyl, R a R b N-carbonyl-; and wherein said C 1-6 alkyl may be optionally substituted by fluorine, hydroxyl, cyano;

Assignees

• Cramp Susan Mary
• Dyke Hazel Joan
• Pallin Thomas David
• Zahler Robert
• Zafgen Inc

Inventors

• Cramp Susan Mary
• Dyke Hazel Joan
• Pallin Thomas David
• Zahler Robert

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K31/4745

  condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48) · CPC title

• C07D498/04

  Ortho-condensed systems · CPC title

• A61K31/5383 Primary

  ortho- or peri-condensed with heterocyclic ring systems · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title